Turci R., Sottani C., Spagnoli G., Minoia C.Biological and environmental monitoring of hospital personnel exposed to antineoplastic agent: a review of analytical methods. J Chromatogr B Biomed Sci Appl2003; 789: 169—209.
2.
ASTM (American Society for Testing and Materials)D666—01 ``Standard Practice for Field Collection of Organic Compounds from Surface Using Wipe Sampling,"'ASTM International . 2005 Available at: www.astm.org . Accessed January 2007.
3.
OSHA (Occupational Safety and Health Administration).Evaluation Guidelines for Surface Sampling Methods. Available at: http://osha.gov/dts/sltc/methods/surfacesampling/surfacesampling.html . Accessed February 2007.
4.
Sessink Pjm, Anzion RB, van der Broek Phh, Bos RPDetection of contamination with antineoplastic agents in a hospital pharmacy department. Pharm Weekbi [Sci]1992; 14: 16—22.
5.
Nygren O., Lundgren C.Determination of platinum in workroom air and in blood and urine from nursing staff attending patients receiving cisplatin chemotherapy. Int Arch Occup Environ Health1997; 70: 209—14.
6.
Schmaus G., Schierl R., Funck S.Monitoring surface contamination by antineoplastic drugs using gas chromatography-mass spectrometry and voltammetry. Am J Health Syst Pharm2002; 59: 956—61.
7.
Minoia C., Turci R., Sottani C., et al. Application of high performance liquid chromatography/tandem mass spectrometry in the environmental and biological monitoring of healthcare personnel occupationally exposed to cyclophosphamide and ifosfamide. Rapid Commun Mass Spectrom1998; 12: 1485—93.
8.
Spezia S., Bocca B., Forte G., et al. Comparison of inductively coupled plasma mass spectrometry techniques in the determination of platinum in urine: quadrupole vs. sector field. Rapid Commun Mass Spectrom2005; 19: 1551—56.
9.
Sessink Pjm, Boer KA, Scheefhals AP, Anzion RB, Bos RPOccupational exposure to antineoplastic agents at several departments in a hospital: environmental contamination and excretion of cyclophosphamide and ifosfamide in urine of exposed workers. Int Arch Occup Environ Health1992; 64: 105—12.
Pethran A., Hauff K., Hessel H., Grimm C-H.Biological, cytogenetic, & ambient monitoring of exposure to antineoplastic drugs. J Oncol Pharm Pract1998; 4: 57.
12.
Rubino FM, Floridia L., Pietropaolo AM, Tavazzani M., Colombi A.Measurement of surface contamination by certain antineoplastic drugs using high-performance liquid chromatograpy: Applications in occupational hygiene investigations in hospital environments. Med Lav1999; 90: 572—83.
13.
Sessink Pjm , Bos RPDrugs hazardous to healthcare workers: Evaluation of methods for monitoring occupational exposure to cytostatic drugs. Drug Saf1999; 20: 347—59.
14.
Connor TH, Anderson RW, Sessink PJ, Broadfield L., Power LASurface contamination with antineoplastic agents in six cancer treatment centers in Canada, & the United States. Am J Health Syst Pharm1999; 56: 1427—32.
15.
Micoli G., Turci R., Arpellini M., Minoia C.Determination of 5-fluorouracil in environmental samples by solid-phase extraction, & high-performance liquid chromatography with untraviolet detection. J Chromatogr B Biomed Sci Appl2001; 750: 25—32.
16.
Vandenbroucke J., Robays H.How to protect environment and employees against cytotoxic agents, the UZ Ghent experience. J Oncol Pharm Pract2001; 6: 146—52.
17.
Connor TH, Anderson RW, Sessink PJ, Spivey SMEffectiveness of a closed-system device in containing surface contamination with cyclophosphamide and ifosfamide in an i.v. admixture area. Am J Health Syst Pharm2002; 59: 68—72.
18.
Kiffmeyer TK , Kube C., Opiolka S., Schmidt KG, Schöppe G., Sessink Pjm.Vapor pressures, evaporation behaviour and airborne concentrations of hazardous drugs: implications for occupational safety. Pharmeaceut J2002; 268: 331—37.
19.
Wick C., Slawson MH, Jorgenson JA, Tyler LSUsing a closed-system protective device to reduce personnel exposure to antineoplastic agents. Am J Health Syst Pharm2003; 60: 2314—20.
20.
Zeedijk M., Greijdanus B., Steenstra FB. Uges Dra.Monitoring exposure of cytotoxics on the hospital ward: Measuring surface contamination of four different cytostatic drugs from one wipe sample. EJHP-S (Science)2005; 11: 18—22.
21.
Schulz H., Bigelow S., Dobish R., Chambers C.Antineoplastic agent workplace contamination study: the Alberta Cancer Board Pharmacy Perspective. J Oncol Pharm Pract2005; 11: 101—09.
22.
Ros Jjw, Simons KA, Verzijl JM, de Bijl GA, Pelders MGPractical applications of a validated method of analysis for the detection of traces of cyclophosphamide on injection bottles and at oncological outpatient center. Ziekenhuisfarmacie1997; 13: 168—71.
23.
Hepp R., Gentschew G.External contamination of commercially available cytotoxic drugs. Krankenhauspharmazie1998; 19: 22—27.
24.
Delporte JP , Chenoix P., Hubert Ph.Chemical contamination of the primary packaging of 5-fluorouracil RTU solutions commercially available on the Belgian market . EHP1999; 5: 119—21.
25.
Nygren O., Gustavsson B., Ström L., Friberg A.Cisplatin contamination on the outside of drug vials. Ann Occup Hyg2002; 46: 555—57.
26.
Favier B., Gilles L., Gesage M., Latour JFAnalysis of cyclophosphamide in the urine of antineoplastic drug handlers . Bull Cancer2003; 90: 905—09.
27.
Connor TH, Sessink Pjm, Harrison BR, et al. Surface contamination of chemotherapy drug vials, & evaluation of new vial-cleaning techniques: Results of three studies. Am J Health Syst Pharm2005; 62: 475—84.
28.
Kleinberg ML , Quinn MJAirborne drug levels in a laminar-flow hood . Am J Hosp Pharm1981; 38: 1301—03.
29.
De Werk Neal A., Wadden RA, Chiou WLExposure of hospital workers to aireborne antineoplastic agents. Am J Hosp Pharm1983 ; 40: 597—601.
30.
McDiarmid MA , Egan T., Furio M., Bonacci M., Watts SRSampling for airborne fluorouracil in a hospital drug preparation area. Am J Hosp Pharm1986 ; 43: 1942—45.
31.
Pyy L., Sorsa M., Hakala E.Ambient monitoring of cyclophosphamide in manufacture, & hospitals. Am Ind Hyg Assoc J1988; 49: 314—17.
32.
Stuart A., Stephens AD, Welch L., Sugerbaker PHSafety monitoring of the coliseum technique for heated intraoperative intraperitoneal chemotherapy with mitomycin C. Ann Surg Oncol2002; 9: 186—91.
33.
Larson RR, Khazaeli MB, Dillon HKA new monitoring method using solid sorbent media for evaluation of airborne cyclophosphamide and other antineoplastic agents. Appl Occup Environ Hyg2003; 18: 120—31.
34.
ACGIH (American Conference of Government Industrial Hygienists).Threshold Limit Values for Chemical Substances and Physical Agents Biological Exposure Indices. ACGIH, Cincinnati, OH. 2004.
35.
NIOSH Alert: Preventing occupational exposures to antineoplastic and other hazardous drugs in health care settings2004. U.S. Department of Health and Human Services, Public Health Service, Centers for Disease Control and Prevention, National Institute for Occupational Safety and Health, DHHS (NIOSH) Publication No 2004—165.
36.
The importance of human data in the establishment of occupational exposure limits. Hum Ecol Risk Assess2002 ; 8: 805—22.
37.
Evelo Cta, Bos RP, Peters Jgp, Henderson PTUrinary cyclophosphamide assay as a method for biological monitoring of occupational exposure to cyclophosphamide. Int Arch Occup Environ Health1986; 58: 151—55.
38.
Ensslin AS, Pethran A., Schierl R., Fruhmann G.Urinary platinum in hospital personnel occupationally exposed to platinum-containing antineoplastic drugs. Int Arch Occup Environ Health1994; 65: 342.
39.
Ensslin AS, Stoll Y., Pethran A., Pfaller A., Rommelt H., Fruhmann G.Biological monitoring of cyclophosphamide and ifosfamide in urine of hospital personnel occupationally exposed to cytostatic drugs. Occup Environ Med1994; 51: 229—33.
40.
Sessink Pjm , Cerná M., Rössner P., et al. Urinary cyclophosphamide excretion and chromosomal aberrations in peripheral blood lymphocytes after occupational exposure to antineoplastic agents. Mutat Res1994; 309: 193—99.
41.
Sessink Pjm , Van de Kerkhof Mca, Anzion RB, Noordhoek J., Bos RPEnvironmental contamination and assessment of exposure to antineoplastic agents by determination of cyclophosphamide in urine of exposed pharmacy technicians: Is skin absorption an important exposure route?Arch Environ Health1994; 49: 165—69.
42.
Mader RM, Rizovski B., Steger GG, Wachter A., Kotz R., Rainer H.Exposure of oncologic nurses to methotrexate in the treatment of osteosarcoma . Arch Environ Health1996; 51: 310—14.
43.
Ensslin AS, Huber R., Pethran A., et al. Biological monitoring of hospital pharmacy personnel occupationally exposed to cytostatic drugs: urinary excretion and cytogenetics studies. Int Arch Occup Environ Health1997; 70: 205—08.
44.
Sessink Pjm, Wittenhorst Bcj, Anzion Rbm, Bos RPExposure of pharmacy technicians to antineoplastic agents: reevaluation after additional protective measures. Arch Environ Health1997; 52(3): 240—44.
45.
Burgaz S., Karahalil B., Bayrak P., et al. Urinary cyclophosphamide excretion and micronuclei frequencies in periperal lymphocytes and in exfoliated buccal epithelial cells of nurses handling antineoplastics. Mutat Res1999; 439: 97—104.
46.
Minoia C., Turci R., Sottani C., et al. Risk assessment concerning hospital personnel participating in the preparation and administration of antineoplastic drugs. (in Italian) . Giornale Italiano di Medicina del Lavoro ed Ergonomia1999; 21: 93—107.
47.
Deschamps F. , Marinutti-Liberge and Lamiable D.Biological monitoring of occupational exposure to cytostatic drugs with platinum. Cancer Detect Prev Online . Available at: http://www.cancerprev.org/Journal/Issues/26/101/1193/4393 . Accessed January 2007.
48.
Turci R., Sottani C., Ronchi A., Minoia C.Biological monitoring of hospital personnel occupationally exposed to antineoplastic agents. Toxicol Lett2002; 134: 57—64.
Pethran A., Schierl R., Hauff K., Grimm C-H., Boos K-S., Nowak D.Uptake of antineoplastic agents in pharmacy and hospital personnel. Part I: Monitoring of urinary concentrations. IntArch Environ Health2003; 76: 5—10.
51.
Mason HJ, Blair S., Sams C., et al. Exposure to antineoplastic drugs in two UK hospital pharmacy units. Ann Occup Hyg2005; 49: 603—10.
52.
Kromhout H. , Hoek F., Uitterhoeve R., et al. Postulating a dermal pathway for exposure to antineoplastic drugs among hospital workers. Applying a conceptual model to the results of three workplace surveys. Ann Occup Hyg2000; 44: 551—60.
53.
Spivey S., Connor THDetermination of sources of workplace contamination with antineoplastic drugs and comparison of conventional IV drug preparation versus a closed system . Hosp Pharm2003; 38: 135—39.
54.
Harrison BR , Godefroid RJ, Kavanaugh EAQuality-assurance testing of staff pharmacists handling cytotoxic drugs. Am J Health Syst Pharm1996; 53: 402—07.
55.
BonabryP.Use of a tracer for handling techniques assessement. Workshop plenary session lecture presented at: 4th European GERPAC conference ; October 4—6, 2006; Presq'ile de Giens Hye'res.
